Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.